On July 17, Alnylam Pharmaceuticals fell 5.04% in regular trading, trading at $268.73 USD/share, with Turnover of $174 million.

Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector performance was weak. Among individual stocks, AbbVie up 0.59%, Amgen down 2.49%, Gilead Sciences down 1.05%, Vertex Pharmaceuticals down 0.37%, Regeneron Pharmaceuticals down 0.89%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)